Tous Actualités
Suivre
Abonner ProBioGen AG

ProBioGen AG

ProBioGen, Germany and Minapharm, Egypt enter into development and co-promotion agreements

Berlin (ots)

ProBioGen and Minapharm jointly announced today
that they have entered into two separate agreements to develop two
therapeutic proteins, one exclusively for Minapharm and another
second generation biopharmaceutical product for co-promotion. In the
first agreement, ProBioGen will apply its proven cell generation
process for biopharmaceutical cell lines. Minapharm, via its
subsidiary, Rhein-Minapharm-Biogenetics, will carry out the pertinent
process research & development, production and commercialization of
the target therapeutic proteins.
In the second agreement, ProBioGen and Minapharm will co-develop a
second generation biopharmaceutical product using either ProBioGen's
pre-optimised CHO cell line or its proprietary Human Neuronal Cell
Line AGE1.HN. Minapharm will exclusively market the product in Middle
Eastern and African countries while ProBioGen will have promotional
rights in Rest of the World. Both companies will also share the
revenue from the product. Further financial details are not
disclosed.
"These two agreements provide a very strong bond between our two
companies and represent a significant step forwards in the
development of our company with access to product revenue in majors
markets such as Europe, America and Japan." said Michael Schlenk, CEO
of ProBioGen.
Dr. Wafik Bardissi, CEO of Minapharm added, "This event further
substantiates Minapharm's position at the regional forefront of
research, development and marketing of innovative recombinant DNA
products. It also coincides with the German-Egyptian Year of Science
and Technology "2007" designated by both governments while
strengthening tides between our company and one of the leading German
biotech companies."

Contact:

ProBioGen AG
Hing Kin Chan, PhD
Goethestraße 54
13086 Berlin
Tel.: +49-30-924006-0
Fax: +49-30-924006-19
e-mail: hingkin.chan@probiogen.de